Naviter Wealth LLC Boosts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Naviter Wealth LLC increased its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 33.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,466 shares of the company’s stock after buying an additional 17,462 shares during the period. Naviter Wealth LLC’s holdings in Takeda Pharmaceutical were worth $965,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. Rise Advisors LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter valued at approximately $26,000. GAMMA Investing LLC purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth $28,000. Principal Securities Inc. bought a new position in shares of Takeda Pharmaceutical during the 4th quarter worth $28,000. First United Bank & Trust purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $29,000. Finally, Lindbrook Capital LLC raised its holdings in shares of Takeda Pharmaceutical by 40.6% in the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock valued at $58,000 after acquiring an additional 1,174 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.2 %

Shares of Takeda Pharmaceutical stock opened at $13.03 on Wednesday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $16.39. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.11 and a quick ratio of 0.58. The stock has a market cap of $41.24 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 0.36 and a beta of 0.54. The firm’s 50-day moving average is $13.16 and its two-hundred day moving average is $13.88.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.